Starling Oncology, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Starling Oncology, Inc. (DFPH) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$12.76 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-12
- Starling Oncology, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$12.76M.
- Starling Oncology, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$13.58M.
- Starling Oncology, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$17.43M.
- Starling Oncology, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$19.00K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 2 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | -$12.76M 10-K · filed 2026-03-12 | ||
| 2024-12-31 | -$13.58M 10-K · filed 2026-03-12 | ||
| 2023-12-31 | -$17.43M 10-K · filed 2025-03-26 | ||
| 2022-12-31 | -$19.00K 10-K · filed 2024-03-28 | ||
| 2021-12-31 | -$2.44M 10-K · filed 2023-03-16 | ||
| 2020-12-31 | -$3.11M 10-K · filed 2022-03-11 | -$90.24K 10-K · filed 2021-03-30 | |
| 2019-12-31 | -$483.00 10-K/A · filed 2021-12-14 |